Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Abstract:
Only two years ago an American-Dutch research effort was the first trialling nanotherapy in cardiovascular patients. Since then they took some remarkable steps towards the use of a combination of endogenous nanoparticles and cannabinoids to treat atherosclerosis. Ground-breaking projects demand innovative ways to create publicity and gather funding. The non-profit organization High on Nano aims to crowd fund a documentary about this topic to support the research.

High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Amsterdam, Netherlands | Posted on December 4th, 2013

The development of nanotechnologies to encapsulate drugs in tiny nanoparticles has witnessed tremendous growth in the last two decades. These nanoparticles are designed for accurate delivery of imaging agents and/or drugs at diseased sites, increasing precision hits while hopefully lowering side effects. Unfortunately the large amount of promising research projects -mainly focusing on oncologic targets- only reported limited clinical successes so far.

For the exploration of nanotechnology in cardiovascular medicine the Dutch chemist Willem Mulder founded the Nanomedicine Laboratory at the Icahn School of Medicine at Mount Sinai in 2006. The nanoparticle platforms his team develops are designed to specifically target atherosclerotic plaques, the underlying cause of cardiovascular disease. In cooperation with the Academic Medical Center in Amsterdam the first-in-man trials with synthetic nanoparticles were initiated already in 2011. In preclinical studies the exploitation of endogenous nanoparticles has shown promise in the context of cardiovascular disease, as such nanoparticles exhibit a natural affinity for atherosclerotic plaques. These particles create an attractive and natural drug delivery platform for atherosclerotic targets.

One of the potent anti-atherosclerotic drug classes they investigate is cannabinoids. In 2005 a seminal study published in the journal Nature demonstrated that low dose oral cannabinoid therapy reduces the progression of atherosclerosis in mice. However, research activity in this area has been relatively subdued. This may be -in part- attributed to psychotropic side effects, and poor specificity and bioavailability of orally administered cannabinoids. To overcome these limitations, nanoparticle formulations may offer an attractive alternative.

Atherosclerosis is also known as ‘hardening' of the arteries. It is a result of genetics, high cholesterol, high blood pressure and smoking cigarettes. It is a common underlying cause of cardiovascular diseases, including heart attack and stroke, and represents the highest expenditure of the world health care (app €198 billion in EU and $300 billion in the US).

Every year about 1,3 million people die from cardiovascular disease in the US and 1,6 million in Europe.

In patients who suffered a heart attack the recurrence risk of an acute coronary syndrome is high, particularly within the first three years when recurrence rates are up to over 20%.

The Dutch Non-profit organization High on Nano was founded on October 28th. Their goal is to popularise the work of Willem Mulder and his teams by developing a documentary (series) about his work.

####

About www.HighonNano.com
To support this project, non-profit organization High on Nano was recently founded. Their aim is to familiarize the general public with this exciting field and establish innovative mechanisms to help fund the research. The first step is crowd funding a documentary to show the world what is going on in the field of 21st century nanomedicine. They hope this process, and the resulting publicity, ultimately open up ways to fund part of the research.

For more information, please click here

Contacts:
Gert van Kempen
Chairman
Non-profit Organization High on Nano

http://www.facebook.com/HighonNano

Copyright © www.HighonNano.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Article:

Clinical trials:

Clinical trials:

Article:

Abstract:

Related News Press

News and information

Timekeeping theory combines quantum clocks and Einstein's relativity: Research reveals new time dilation phenomenon October 23rd, 2020

New test method to standardize immunological evaluation of nucleic acid nanoparticles: Researchers believe accurate, affordable and easily reproduced protocol for assessing immune effects could further research collaboration and advance therapeutic use of new medicines October 23rd, 2020

Cicada-inspired waterproof surfaces closer to reality, researchers report October 23rd, 2020

Trailblazing theoretical physicist Sylvester James Gates Jr. is among speakers at nanotechnology symposium: Annual event moves to virtual format, open to attendees worldwide at no charge Oct. 29 October 23rd, 2020

Videos/Movies

Octopus-inspired sucker transfers thin, delicate tissue grafts and biosensors October 16th, 2020

Materials scientists learn how to make liquid crystal shape-shift September 25th, 2020

Engineers produce a fisheye lens that's completely flat: The single piece of glass produces crisp panoramic images September 22nd, 2020

Physicists find misaligned carbon sheets yield unparalleled properties July 31st, 2020

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Invests Additional Capital in TheMaven, Inc. and Provides QTD Public Portfolio Update (+22.1% / +$0.32 Per Share) September 10th, 2020

180 Degree Capital Corp. to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020 and to Host a Conference Call on Tuesday, August 11, 2020 August 7th, 2020

Izon Science receives $10.5M investment from Bolton Equities: Christchurch-headquartered nanotech company secures investment to accelerate global growth; appoints top board chairman and directors July 28th, 2020

Nanomedicine

New test method to standardize immunological evaluation of nucleic acid nanoparticles: Researchers believe accurate, affordable and easily reproduced protocol for assessing immune effects could further research collaboration and advance therapeutic use of new medicines October 23rd, 2020

Octopus-inspired sucker transfers thin, delicate tissue grafts and biosensors October 16th, 2020

Controlling the speed of enzyme motors brings biomedical applications of nanorobots closer: Recent advances in this field have made micro- and nanomotors promising devices for solving many biomedical problems October 13th, 2020

New drug carrier systems: University of Delaware researchers advance drug delivery systems to treat connective tissue disorders October 9th, 2020

Announcements

Timekeeping theory combines quantum clocks and Einstein's relativity: Research reveals new time dilation phenomenon October 23rd, 2020

New test method to standardize immunological evaluation of nucleic acid nanoparticles: Researchers believe accurate, affordable and easily reproduced protocol for assessing immune effects could further research collaboration and advance therapeutic use of new medicines October 23rd, 2020

Cicada-inspired waterproof surfaces closer to reality, researchers report October 23rd, 2020

Trailblazing theoretical physicist Sylvester James Gates Jr. is among speakers at nanotechnology symposium: Annual event moves to virtual format, open to attendees worldwide at no charge Oct. 29 October 23rd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project